{"id":"NCT03717194","sponsor":"Soo Lim","briefTitle":"Effect of Ertugliflozin on Cardiac Function in Diabetes","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-01","primaryCompletion":"2022-12-31","completion":"2023-04-30","firstPosted":"2018-10-24","resultsPosted":"2024-11-20","lastUpdate":"2024-11-20"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type2 Diabetes","Heart Failure"],"interventions":[{"type":"DRUG","name":"Ertugliflozin","otherNames":["Steglatro"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ertugliflozin","type":"EXPERIMENTAL"},{"label":"Control group","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic medications including DPP4 inhibitors.","primaryOutcome":{"measure":"Left Ventricular Global Longitudinal Strain (LVGLS)","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Ertugliflozin Group","deltaMin":16.6,"sd":2.8},{"arm":"Control Group","deltaMin":16.4,"sd":2.6}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["26378978","29166232","25978372","11834347","25533754","20650361","2936235","16376782","19187853","15163933","28678927","28185312","39438942"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Urinary tract infection","Hypoglycemia","Genital infection","Dehydration"]}}